Your browser doesn't support javascript.
loading
Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade.
McKay, Rana R; Montgomery, Bruce; Xie, Wanling; Zhang, Zhenwei; Bubley, Glenn J; Lin, David W; Preston, Mark A; Trinh, Quoc-Dien; Chang, Peter; Wagner, Andrew A; Mostaghel, Elahe A; Kantoff, Philip W; Nelson, Peter S; Kibel, Adam S; Taplin, Mary-Ellen.
Afiliação
  • McKay RR; Department of Medicine, Division of Hematology/Oncology, University of California San Diego, San Diego, CA, USA.
  • Montgomery B; Department of Medicine, Division of Oncology, University of Washington, Seattle, WA, USA.
  • Xie W; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Zhang Z; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Bubley GJ; Department of Medicine, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Lin DW; Department of Urology, University of Washington, Seattle, WA, USA.
  • Preston MA; Department of Surgery, Division of Urology, Dana Farber/Brigham and Women's Cancer Center, Boston, MA, USA.
  • Trinh QD; Department of Surgery, Division of Urology, Dana Farber/Brigham and Women's Cancer Center, Boston, MA, USA.
  • Chang P; Department of Urology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Wagner AA; Department of Urology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Mostaghel EA; Department of Medicine, Division of Oncology, University of Washington, Seattle, WA, USA.
  • Kantoff PW; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Nelson PS; Department of Medicine, Division of Oncology, University of Washington, Seattle, WA, USA.
  • Kibel AS; Department of Surgery, Division of Urology, Dana Farber/Brigham and Women's Cancer Center, Boston, MA, USA.
  • Taplin ME; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Mary_Taplin@DFCI.harvard.edu.
Prostate Cancer Prostatic Dis ; 21(3): 364-372, 2018 09.
Article em En | MEDLINE | ID: mdl-29263420
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Calicreínas / Antígeno Prostático Específico / Terapia Neoadjuvante / Antagonistas de Androgênios / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Humans / Male / Middle aged Idioma: En Revista: Prostate Cancer Prostatic Dis Assunto da revista: ENDOCRINOLOGIA / NEOPLASIAS / UROLOGIA Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Calicreínas / Antígeno Prostático Específico / Terapia Neoadjuvante / Antagonistas de Androgênios / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Humans / Male / Middle aged Idioma: En Revista: Prostate Cancer Prostatic Dis Assunto da revista: ENDOCRINOLOGIA / NEOPLASIAS / UROLOGIA Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Estados Unidos